Literature DB >> 12629125

Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration.

Giovanni Vitale1, Gelsy Arianna Lupoli, Antonio Ciccarelli, Antonio Lucariello, Maria Rosa Fittipaldi, Francesco Fonderico, Annalisa Panico, Giovanni Lupoli.   

Abstract

Recombinant human TSH (rhTSH) has been proposed as an alternative method to the withdrawal of thyroid hormones in the follow-up of differentiated thyroid cancer. The aim of the present study was to evaluate the influence of several demographic and anthropometric parameters [age, body weight, height, body mass index, and body surface area (BSA)] on serum peak TSH levels after rhTSH administration. rhTSH was administered to 112 patients with differentiated thyroid carcinoma according to the conventional two-dose schedule (0.9 mg/d). Serum TSH levels were measured 24 h before and after the first administration of rhTSH, and then 24, 48, and 72 h after the second administration of rhTSH. In one severely obese patient, serum peak TSH values did not reach a valid stimulation range. Serum peak TSH levels were negatively related to body weight (r = -0.69; P < 0.0001), body mass index (r = -0.51; P < 0.0001), and BSA (r = -0.72; P < 0.0001). In a multivariate regression analysis including demographic and anthropometric variables, only BSA was independently associated to serum peak TSH concentrations (standardized beta coefficient = -0.721; P < 0.0001). In conclusion, body size seems to influence serum peak TSH levels after rhTSH administration. Future studies should evaluate the possibility of using personalized rhTSH doses, adjusted in relation to BSA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12629125     DOI: 10.1210/jc.2002-020953

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Successful use of recombinant human thyrotropin in the therapy of pediatric well-differentiated thyroid cancer.

Authors:  M Ralli; P Cohan; K Lee
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

2.  Age modifies the response to recombinant human thyrotropin.

Authors:  Rebecca Over; Hala Nsouli-Maktabi; Kenneth D Burman; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2010-10-18       Impact factor: 6.568

Review 3.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

4.  Analysis of Clinical Factors for the Determination of Optimal Serum Level of Thyrotropin After Recombinant Human Thyroid-Stimulating Hormone Administration.

Authors:  Seung Hyun Son; Sang-Woo Lee; Ji-Hoon Jung; Choon-Young Kim; Do-Hoon Kim; Shin Young Jeong; Byeong-Cheol Ahn; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2015-09-01

5.  Recombinant human thyroid stimulating hormone in 2008: focus on thyroid cancer management.

Authors:  Ann Gramza; Kathryn G Schuff
Journal:  Onco Targets Ther       Date:  2009-01-01       Impact factor: 4.147

6.  Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study.

Authors:  Agnese Barnabei; Lidia Strigari; Agnese Persichetti; Roberto Baldelli; Laura Rizza; Claudia Annoscia; Rosa Lauretta; Giovanni Cigliana; Maddalena Barba; Aurora De Leo; Marialuisa Appetecchia; Francesco Torino
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-15       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.